Evolving Therapeutic Strategies with Next-Generation Anti-VEGF Agents in Retinal

This segment examines how the advent of higher-dose and dual-pathway anti-VEGF agents has reshaped treatment strategies for retinal vascular diseases. The discussion underscores how aflibercept 8 mg and faricimab have improved anatomic outcomes and extended dosing intervals, offering meaningful—though patient-specific—reductions in treatment burden. Clinicians describe seeing faster retinal drying, enhanced durability, and better fluid control, particularly in treatment-naïve patients with neovascular AMD. However, they note that some “frequent flyers” still require close follow-up, reflecting ongoing unmet needs in durability. The conversation also highlights how pivotal trial designs, such as those for PULSAR and TENAYA/LUCERNE, have influenced real-world practice—encouraging earlier extension of dosing intervals and renewed emphasis on loading doses. Participants agree that these agents enable more flexible and confident interval management, while also challenging step-therapy policies that delay access to next-generation options that could improve long-term outcomes and overall care efficiency.